Dimension Capital Closes $800M Fund for Science-Compute Nexus

Dimension Capital, a venture firm established in late 2022, has rapidly secured its third and largest fund to date, amassing $800 million. This significant capital raise underscores the firm's conviction in the accelerating convergence of scientific innovation and computational power. The new fund represents a 60% increase over its prior $500 million vehicle, which was closed just 18 months ago, signaling strong investor confidence in Dimension's strategy.

Founded by former Lux Capital partners Zavian Dar and Adam Goulburn, alongside Obvious Ventures alumnus Nan Li, the firm's core thesis centers on the burgeoning potential of deep-tech companies operating at the confluence of life sciences and advanced software. The partners have expressed surprise at the swift validation of their vision, observing a pronounced trend of founders prioritizing ventures that bridge these traditionally distinct domains.

The firm's investment portfolio reflects this focus. Notably, Dimension co-led a $30 million seed round for Chai Discovery, a startup developing open-source AI models for drug discovery. Chai Discovery recently announced a substantial $400 million raise at a $3.8 billion valuation, highlighting the market's appetite for AI-driven pharmaceutical innovation. Another key investment is in New Limit, an anti-aging venture co-founded by Coinbase CEO Brian Armstrong. New Limit recently concluded its Series C funding at a $3.1 billion valuation, following Dimension's initial Series A backing in early 2025.

Further demonstrating its strategic positioning, Dimension Capital also holds an interest in Anthropic, a leading AI safety and research company. This stake was acquired when Dimension's portfolio company, drug discovery platform Coefficient Bio, was reportedly acquired by Anthropic for approximately $400 million earlier this spring. The firm also counts inference technology provider Modal Labs among its investments, showcasing a diversified approach within the compute-driven science sector.

The rapid growth of Dimension Capital and the success of its portfolio companies align with broader market trends. The global biotechnology market is projected to expand significantly, driven by advancements in genomics, personalized medicine, and AI-powered research. Similarly, the AI sector continues its exponential trajectory, with substantial investments flowing into foundational models and specialized applications. The intersection of these fields, where complex biological challenges are tackled with cutting-edge computational tools, represents a particularly fertile ground for venture capital, attracting substantial capital and fostering groundbreaking innovation.

Dimension Capital's latest fundraise positions it to capitalize further on this dynamic market. By providing capital to companies at the forefront of scientific discovery and computational advancement, the firm aims to support the development of transformative technologies. The increasing size of its funds suggests a strategy of taking larger stakes in a curated set of high-potential companies, aiming to generate significant returns as these ventures mature and address critical global challenges in health, sustainability, and beyond.